Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer

Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer ORIGINAL ARTICLE Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer Paul De Leyn, MD, PhD,* Johan Vansteenkiste, MD, PhD,† Yolande Lievens, MD, PhD,‡ Dirk Van Raemdonck, MD, PhD,* Philippe Nafteux, MD,* Georges Decker, MD,* Willy Coosemans, MD, PhD,* Herbert Decaluwe´, MD,* Johny Moons, MScM,* and Tony Lerut, MD, PhD* Key Words: Lung cancer, Superior sulcus, T4, Trimodality treat- Introduction: For sulcus superior tumors and central cT4 tumors, ment, induction therapy. low resectability and poor long-term survival rates are obtained with single-modality treatment. (J Thorac Oncol. 2009;4: 62–68) Methods: Analysis of all consecutive patients in our prospective database, who had potentially resectable superior sulcus (cT3–T4) and central cT4 tumors and were treated with induction chemora- umors of the superior sulcus and central T4 tumors are an diotherapy (two courses of cisplatin-etoposide) and concomitant Tuncommon subset of non-small cell lung cancer radiotherapy (45 Gy/1.8 Gy) after multidisciplinary discussion. (NSCLC). If surgery is performed, a major problem is to Surgery with attempted complete resection was performed in pa- obtain a complete resection with clear margins. In superior sulcus tumors, there is the proximity of critical structures, tients showing response or stable disease on computed tomography. such http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer

Lerut, Tony
Journal of Thoracic Oncology , Volume 4 (1) – Jan 1, 2009
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/survival-after-trimodality-treatment-for-superior-sulcus-and-central-QcHQSlh0zt

References (31)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181914d52
pmid
19096308
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer Paul De Leyn, MD, PhD,* Johan Vansteenkiste, MD, PhD,† Yolande Lievens, MD, PhD,‡ Dirk Van Raemdonck, MD, PhD,* Philippe Nafteux, MD,* Georges Decker, MD,* Willy Coosemans, MD, PhD,* Herbert Decaluwe´, MD,* Johny Moons, MScM,* and Tony Lerut, MD, PhD* Key Words: Lung cancer, Superior sulcus, T4, Trimodality treat- Introduction: For sulcus superior tumors and central cT4 tumors, ment, induction therapy. low resectability and poor long-term survival rates are obtained with single-modality treatment. (J Thorac Oncol. 2009;4: 62–68) Methods: Analysis of all consecutive patients in our prospective database, who had potentially resectable superior sulcus (cT3–T4) and central cT4 tumors and were treated with induction chemora- umors of the superior sulcus and central T4 tumors are an diotherapy (two courses of cisplatin-etoposide) and concomitant Tuncommon subset of non-small cell lung cancer radiotherapy (45 Gy/1.8 Gy) after multidisciplinary discussion. (NSCLC). If surgery is performed, a major problem is to Surgery with attempted complete resection was performed in pa- obtain a complete resection with clear margins. In superior sulcus tumors, there is the proximity of critical structures, tients showing response or stable disease on computed tomography. such

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jan 1, 2009

There are no references for this article.